3.9 Article

Liposome-based DNA carriers may induce cellular stress response and change gene expression pattern in transfected cells

期刊

BMC MOLECULAR BIOLOGY
卷 12, 期 -, 页码 -

出版社

BIOMED CENTRAL LTD
DOI: 10.1186/1471-2199-12-27

关键词

-

资金

  1. [1/0-PBZ-MNiI-2/1/2005]

向作者/读者索取更多资源

Background: During functional studies on the rat stress-inducible Hspa1b (hsp70.1) gene we noticed that some liposome-based DNA carriers, which are used for transfection, induce its promoter activity. This observation concerned commercial liposome formulations (LA), Lipofectin and Lipofectamine 2000. This work was aimed to understand better the mechanism of this phenomenon and its potential biological and practical consequences. Results: We found that a reporter gene driven by Hspa1b promoter is activated both in the case of transient transfections and in the stably transfected cells treated with LA. Using several deletion clones containing different fragments of Hspa1b promoter, we found that the regulatory elements responsible for most efficient LA-driven inducibility were located between nucleotides -269 and +85, relative to the transcription start site. Further studies showed that the induction mechanism was independent of the classical HSE-HSF interaction that is responsible for gene activation during heat stress. Using DNA microarrays we also detected significant activation of the endogenous Hspa1b gene in cells treated with Lipofectamine 2000. Several other stress genes were also induced, along with numerous genes involved in cellular metabolism, cell cycle control and pro-apoptotic pathways. Conclusions: Our observations suggest that i) some cationic liposomes may not be suitable for functional studies on hsp promoters, ii) lipofection may cause unintended changes in global gene expression in the transfected cells.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Chemistry, Physical

Cell-Mediated Immunoreactivity of Poly(2-isopropenyl-2-oxazoline) as Promising Formulation for Immunomodulation

Ema Paulovicova, Zuzana Kronekova, Lucia Paulovicova, Monika Majercikova, Juraj Kronek

Summary: Poly(2-isopropenyl-2-oxazoline) (PIPOx) is a functional polymer with high potential for drug delivery, tissue engineering, and immunomodulation. In vitro studies have shown the immunomodulatory efficiency of PIPOx formulation on various immune cell responses, including the production of specific cytokines and cell phagocytosis. The results demonstrate the bioavailability of PIPOx and its capability to induce immune cell responses, highlighting its potential for future biomedical applications.

MATERIALS (2021)

Article Polymer Science

Effect of Dexamethasone on Thermoresponsive Behavior of Poly(2-Oxazoline) Diblock Copolymers

Monika Majercikova, Peter Nadazdy, Dusan Chorvat, Leonid Satrapinskyy, Helena Valentova, Zuzana Kronekova, Peter Siffalovic, Juraj Kronek, Anna Zahoranova

Summary: This study investigated the influence of dexamethasone on the thermoresponsive behavior of diblock copolymers, revealing that the addition of dexamethasone lowered the cloud point temperature of one copolymer and resulted in the formation of microparticles. The characteristics of the microparticles were influenced by the structure and concentration of the copolymer, the drug concentration, and the temperature.

POLYMERS (2021)

Article Endocrinology & Metabolism

Diagnosis and treatment of thyroid cancer in adult patients - Recommendations of Polish Scientific Societies and the National Oncological Strategy. 2022 Update

Barbara Jarzab, Marek Dedecjus, Andrzej Lewinski, Zbigniew Adamczewski, Elwira Bakula-Zalewska, Agata Baldys-Waligorska, Marcin Barczynski, Magdalena Biskup-Fruzynska, Barbara Bobek-Billewicz, Artur Bossowski, Monika Buziak-Bereza, Ewa Chmielik, Agnieszka Czarniecka, Rafal Czepczynski, Jaroslaw Cwikla, Katarzyna Dobruch-Sobczak, Janusz Dzieciol, Aneta Gawlik, Jacek Gawrychowski, Daria Handkiewicz-Junak, Jerzy Harasymczuk, Alicja Hubalewska-Dydejczyk, Joanna Januszkiewicz-Caulier, Michal Jarzab, Krzysztof Kaczka, Michal Kalemba, Grzegorz Kaminski, Malgorzata Karbownik-Lewinska, Andrzej Kawecki, Aneta Kluczewska-Galka, Agnieszka Kolasinska-Cwikla, Magdalena Kolton, Aleksander Konturek, Beata Kos-Kudla, Agnieszka Kotecka-Blicharz, Aldona Kowalska, Jolanta Krajewska, Andrzej Kram, Leszek Krolicki, Aleksandra Kukulska, Michal Kusinski, Krzysztof Kuzdak, Dariusz Lange, Aleksandra Ledwon, Ewa Malecka-Tendera, Przemyslaw Mankowski, Bartosz Migda, Marek Niedziela, Malgorzata Oczko-Wojciechowska, Dariusz Polnik, Lech Pomorski, Marek Ruchala, Konrad Samborski, Anna Skowronska-Szczesniak, Agata Stanek-Widera, Ewa Stobiecka, Zoran Stojcev, Magdalena Suchorzepka-Simek, Anhelli Syrenicz, Ewelina Szczepanek-Parulska, Malgorzata Trofimiuk-Muldner, Andrzej Tysarowski, Andrzej Wygoda, Klaudia Zajkowska, Ewa Zembala-Nozynska, Agnieszka Zylka

Summary: The "Thyroid Cancer 2022" guidelines are based on previous Polish recommendations and consider international guidelines such as ATA 2015 and NCCN. The changes in the Polish recommendations include the inclusion of international guidelines and scientifically proven studies. These changes allow for a personalized approach in low-risk thyroid carcinoma treatment, update the criteria for preoperative diagnosis, and provide updated rules for postoperative treatment and monitoring. The focus is on maintaining treatment efficacy while ensuring the best possible quality of life for patients after thyroid cancer treatment.

ENDOKRYNOLOGIA POLSKA (2022)

Article Oncology

Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial

Jens Huober, Carlos H. Barrios, Naoki Niikura, Michal Jarzab, Yuan-Ching Chang, Shannon L. Huggins-Puhalla, Jose Pedrini, Lyudmila Zhukova, Vilma Graupner, Daniel Eiger, Volkmar Henschel, Nino Gochitashvili, Chiara Lambertini, Eleonora Restuccia, Hong Zhang

Summary: This study investigated the efficacy of combining atezolizumab with chemotherapy in high-risk, HER2-positive early breast cancer patients. Results showed that atezolizumab did not increase pCR rates in either the ITT or PD-L1-positive populations, and more adverse events were seen in the atezolizumab group. Therefore, PH and chemotherapy remain the standard of care for these patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Cell Biology

HSF1 Can Prevent Inflammation following Heat Shock by Inhibiting the Excessive Activation of the ATF3 and JUN&FOS Genes

Patryk Janus, Pawel Kus, Natalia Vydra, Agnieszka Toma-Jonik, Tomasz Stokowy, Katarzyna Mrowiec, Bartosz Wojtas, Bartlomiej Gielniewski, Wieslawa Widlak

Summary: This study investigates the impact of HSF1 levels on the response to proteotoxic stress in breast cancer cells. HSF1 deficiency impairs the overall transcriptional response to heat shock but enhances the stress-induced activation of certain genes and the heat shock-induced inflammatory response. The study also identifies potential cell-type-specific mechanisms in the regulation of HSF1-dependent genes.
Article Biochemistry & Molecular Biology

Microfibril Associated Protein 5 (MFAP5) Is Related to Survival of Ovarian Cancer Patients but Not Useful as a Prognostic Biomarker

Katarzyna Aleksandra Kujawa, Ewa Zembala-Nozynska, Joanna Patrycja Syrkis, Alexander Jorge Cortez, Jolanta Kupryjanczyk, Katarzyna Marta Lisowska

Summary: This study aimed to validate the MFAP5 gene and protein as a potential prognostic biomarker for ovarian cancer (OC). The results showed that higher expression of MFAP5 was associated with advanced stages and high-grade tumors, and was significantly correlated with shorter survival. Although not suitable as a prognostic biomarker for evaluation with IHC, MFAP5 is worth further studies as a possible therapeutic target.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Oncology

Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer

Marcin Kubeczko, Dorota Gabrys, Marzena Gawkowska, Anna Polakiewicz-Gilowska, Alexander J. Cortez, Aleksandra Krzywon, Grzegorz Wozniak, Tomasz Latusek, Aleksandra Lesniak, Katarzyna Swiderska, Marta Mianowska-Malec, Barbara Lanoszka, Konstanty Chomik, Mateusz Gajek, Anna Michalik, Elzbieta Nowicka, Rafal Tarnawski, Tomasz Rutkowski, Michal Jarzab

Summary: CDK4/6 inhibitors can cause bone marrow suppression as a side effect, while radiation therapy may enhance myelotoxicity. The safety of combining CDK4/6 inhibitors with radiotherapy is still uncertain, leading to the suspension of CDK4/6 inhibitors during radiation therapy by many oncologists.

CANCERS (2023)

Article Medicine, General & Internal

Efficacy of CDK 4/6 Inhibitors and Radiotherapy in Breast Cancer Patients with Brain Metastases

Marcin Kubeczko, Michal Jarzab, Aleksandra Krzywon, Donata Graupner, Anna Polakiewicz-Gilowska, Dorota Gabrys

Summary: This study retrospectively evaluated the outcomes of patients with advanced breast cancer who received CDK4/6 inhibitors and radiotherapy to the brain. The findings suggest that the combination of CDK4/6 inhibitors and brain radiotherapy is feasible and may improve progression-free survival and local control. However, further prospective clinical trials are needed to validate these results, as the number of patients treated concurrently was limited.

JOURNAL OF CLINICAL MEDICINE (2023)

Review Oncology

Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis

Marcin Kubeczko, Michal Jarzab, Dorota Gabrys, Aleksandra Krzywon, Alexander J. Cortez, Amy J. Xu

Summary: The addition of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) to endocrine therapy in hormone receptor-positive (HR+) human epidermal growth factor 2-negative (HER2-) breast cancer has shown practice-changing improvements in overall survival. This meta-analysis further confirms the safety and feasibility of CDK4/6i treatment with radiotherapy, suggesting it as a viable treatment option.

RADIOTHERAPY AND ONCOLOGY (2023)

Article Endocrinology & Metabolism

Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours)

Beata Kos-Kudla, Wanda Foltyn, Anna Malczewska, Tomasz Bednarczuk, Marek Bolanowski, Malgorzata Borowska, Ewa Chmielik, Jaroslaw B. Cwikla, Iwona Gisterek, Daria Handkiewicz-Junak, Alicja Hubalewska-Dydejczyk, Michal Jarzab, Roman Junik, Dariusz Kajdaniuk, Grzegorz Kaminski, Agnieszka Kolasinska-Cwikla, Aldona Kowalska, Leszek Krolicki, Maciej Krzakowski, Jolanta Kunikowska, Katarzyna Kusnierz, Andrzej Lewinski, Lukasz Liszka, Magdalena Londzin-Olesik, Bogdan Marek, Anna Nasierowska-Guttmejer, Ewa Nowakowska-Dulawa, Marianne E. Pavel, Joanna Pilch-Kowalczyk, Jaroslaw Regula, Violetta Rosiek, Marek Ruchala, Grazyna Rydzewska, Lucyna Sieminska, Anna Sowa-Staszczak, Teresa Starzynska, Zoran Stojcev, Janusz Strzelczyk, Michal Studniarek, Anhelli Syrenicz, Marek Szczepkowski, Ewa Wachula, Wojciech Zajecki, Anna Zemczak, Wojciech Zgliczynski, Krzysztof Zieniewicz, Barbara Jarzqb

Summary: This article presents general recommendations for the management of neuroendocrine neoplasms and outlines various management strategies for different types of NENs based on expert research results, aiming to provide the optimal treatment for NENs patients.

ENDOKRYNOLOGIA POLSKA (2022)

Article Endocrinology & Metabolism

Neuroendocrine neoplasms of the small intestine and the appendix - update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours)

Tomasz Bednarczuk, Anna Zemczak, Marek Bolanowski, Malgorzata Borowska, Ewa Chmielik, Jaroslaw B. Cwikla, Wanda Foltyn, Iwona Gisterek, Daria Handkiewicz-Junak, Alicja Hubalewska-Dydejczyk, Michal Jarzab, Roman Junik, Dariusz Kajdaniuk, Grzegorz Kaminski, Agnieszka Kolasinska-Cwikla, Karolina Kopacz-Wrobel, Aldona Kowalska, Leszek Krolicki, Jolanta Kunikowska, Katarzyna Kusnierz, Andrzej Lewinski, Lukasz Liszka, Magdalena Londzin-Olesik, Bogdan Marek, Anna Malczewska, Anna Nasierowska-Guttmejer, Ewa Nowakowska-Dulawa, Marianne E. Pavel, Joanna Pilch-Kowalczyk, Jaroslaw Regula, Violetta Rosiek, Marek Ruchala, Grazyna Rydzewska, Lucyna Sieminska, Anna Sowa-Staszczak, Teresa Starzynska, Zoran Stojcev, Janusz Strzelczyk, Michal Studniarek, Anhelli Syrenicz, Marek Szczepkowski, Ewa Wachula, Wojciech Zajecki, Wojciech Zgliczynski, Krzysztof Zieniewicz, Beata Kos-Kudla

Summary: This article presents updated Polish recommendations for the management of patients with neuroendocrine neoplasms of the small intestine and appendix. The small intestine, particularly the ileum, is a common location for these tumors, most of which are well-differentiated and slow-growing. Various imaging and laboratory diagnostic methods can be used for diagnosis, with surgery being the preferred treatment option. Long-acting somatostatin analogues play a crucial role in the medical treatment of both functional and non-functional tumors.

ENDOKRYNOLOGIA POLSKA (2022)

Article Endocrinology & Metabolism

Gastroduodenal neuroendocrine neoplasms including gastrinoma - update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours)

Grazyna Rydzewska, Janusz Strzelczyk, Tomasz Bednarczuk, Marek Bolanowski, Malgorzata Borowska, Ewa Chmielik, Jaroslaw B. Cwikla, Wanda Foltyn, Iwona Gisterek, Daria Handkiewicz-Junak, Alicja Hubalewska-Dydejczyk, Ksenia Janas, Michal Jarzab, Roman Junik, Dariusz Kajdaniuk, Grzegorz Kaminski, Agnieszka Kolasinska-Cwikla, Magorzata Kolos, Aldona Kowalska, Leszek Krolicki, Jolanta Kunikowska, Katarzyna Kusnierz, Andrzej Lewinski, Lukasz Liszka, Magdalena Londzin-Olesik, Bogdan Marek, Anna Malczewska, Anna Nasierowska-Guttmejer, Ewa Nowakowska-Dulawa, Marianne E. Pavel, Joanna Pilch-Kowalczyk, Jaroslaw Regula, Violetta Rosiek, Marek Ruchala, Lucyna Sieminska, Anna Sowa-Staszczak, Teresa Starzynska, Zoran Stojcev, Michal Studniarek, Anhelli Syrenicz, Marek Szczepkowski, Ewa Wachula, Wojciech Zajecki, Anna Zemczak, Wojciech Zgliczynski, Krzysztof Zieniewicz, Beata Kos-Kudla

Summary: Updated recommendations for the management of patients with gastric and duodenal neuroendocrine neoplasms, including gastrinoma, have been issued by the Polish Network of Neuroendocrine Tumours. The recommendations cover the epidemiology, diagnostic procedures, therapeutic management, and the importance of patient monitoring.

ENDOKRYNOLOGIA POLSKA (2022)

Article Endocrinology & Metabolism

Pancreatic neuroendocrine neoplasms-update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours)

Beata Kos-Kudla, Violetta Roseiek, Malgorzata Borowska, Tomasz Bednarczuk, Marek Bolanowski, Ewa Chmielik, Jaroslaw B. Cwikla, Wanda Foltyn, Iwona Gisterek, Daria Handkiewicz-Junak, Alicja Hubalewska-Dydejczyk, Michal Jarzab, Roman Junik, Dariusz Kajdaniuk, Grzegorz Kaminski, Agnieszka Kolasinska-Cwikla, Aldona Kowalska, Leszek Krolicki, Jolanta Kunikowska, Katarzyna Kusnierz, Andrzej Lewinski, Lukasz Liszka, Magdalena Londzin-Olesik, Bogdan Marek, Anna Malczewska, Anna Nasierowska-Guttmejer, Ewa Nowakowska-Dulawa, Marianne E. Pavel, Joanna Pilch-Kowalczyk, Jaroslaw Regula, Marek Ruchala, Grazyna Rydzewska, Lucyna Sieminska, Anna Sowa-Staszczak, Teresa Starzynska, Zoran Stojcev, Janusz Strzelczyk, Michal Studniarek, Anhelli Syrenicz, Marek Szczepkowski, Ewa Wachula, Wojciech Zajecki, Anna Zemczak, Wojciech Zgliczynski, Krzysztof Zieniewicz

Summary: This paper presents the guidelines for the diagnostics and management of pancreatic neuroendocrine neoplasms (PanNENs) developed by Polish experts. It includes biochemical tests, molecular identification, imaging diagnostics, and pharmacological management.

ENDOKRYNOLOGIA POLSKA (2022)

Article Endocrinology & Metabolism

Colorectal neuroendocrine neoplasms-update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours)

Teresa Starzynska, Magdalena Londzin-Olesik, Tomasz Bednarczuk, Marek Bolanowski, Malgorzata Borowska, Ewa Chmielik, Jaroslaw B. Cwikla, Wanda Foltyn, Iwona Gisterek, Daria Handkiewicz-Junak, Alicja Hubalewska-Dydejczyk, Michal Jarzab, Roman Junik, Dariusz Kajdaniuk, Grzegorz Kaminski, Agnieszka Kolasinska-Cwikla, Aldona Kowalska, Leszek Krolicki, Jolanta Kunikowska, Katarzyna Kusnierz, Andrzej Lewinski, Lukasz Liszka, Bogdan Marek, Anna Malczewska, Anna Nasierowska-Guttmejer, Ewa Nowakowska-Dulawa, Marianne E. Pavel, Joanna Pilch-Kowalczyk, Jaroslaw Regula, Violetta Rosiek, Marek Ruchala, Grazyna Rydzewska, Lucyna Sieminska, Anna Sowa-Staszczak, Zoran Stojcev, Janusz Strzelczyk, Michal Studniarek, Anhelli Syrenicz, Marek Szczepkowski, Ewa Wachula, Wojciech Zajecki, Anna Zemczak, Wojciech Zgliczynski, Krzysztof Zieniewicz, Beata Kos-Kudla

Summary: Colorectal neuroendocrine neoplasms (CRNENs), especially rectal tumors, are being diagnosed more frequently due to the widespread use of colonoscopy, including screening examinations. It is important to constantly update and promote the optimal principles of diagnostics and treatment for these tumors.

ENDOKRYNOLOGIA POLSKA (2022)

Article Pathology

GRADE MIGRATION AND IMPORTANT PROGNOSTIC FACTORS IN A PATHOLOGY SPECIMEN FOR RADICAL RADIOTHERAPY IN PROSTATE CANCER PATIENTS

Wojciech Majewski, Dariusz Lange, Agata Stanek-Widera, Bartosz Itrych, Tomasz Krzysztofiak, Michal Jarzab, Malgorzata Oczko-Wojciechowska, Maciej Kajor, Rafal Tarnawski

Summary: This study aimed to evaluate grade migration and prognosis in patients with prostate cancer. Re-evaluation of pathology specimens upgraded the Gleason score in the majority of patients. Grade Group (GG) was a significant factor for biochemical control, while the cribriform pattern had borderline significance. Prostate cancer starts to show aggressive behavior from GG4, and the presence of the cribriform pattern nearly triples the biochemical failure rate.

POLISH JOURNAL OF PATHOLOGY (2022)

暂无数据